Ignacio Garrido-Laguna, Director of Phase 1 Program at Huntsman Cancer Institute, posted on X:
“Today clinic 2 posterchilds clinical trials make difference pancreatic cancer.
1 Kras G12D ongoing complete response multi RAS inhibitor trial for 2.5 years (Cycle 40!!).
2 patient with MTAP LOF >1 year on PRMT5 inhibitor. Focus on impactful clinical research.”